zacks.com · 28 jul

5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio

Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.

seekingalpha.com · 28 jul

Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption

Harmony Biosciences (HRMY) is evolving from a single-product firm into a self-funded neuroscience platform, leveraging robust WAKIX growth. WAKIX posted 30% Q1 revenue growth, supporting a strong balance sheet with $710 million net cash and funding for pipeline expansion. HRMY trades at a deep valuation discount, reflecting market fears of WAKIX cash flow erosion post-2030 and underappreciated pipeline potential.

zacks.com · 28 jul

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com · 27 jul

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

zacks.com · 22 jul

Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

globenewswire.com · 21 jul

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.

zacks.com · 17 jul

HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition

Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.

businesswire.com · 16 jul

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the fi.